ArticleCancer immunology research2017
Metastatic Melanoma Patient Had a Complete Response with Clonal Expansion after Whole Brain Radiation and PD-1 Blockade.
Article in Cancer immunology research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Dawn of Monitoring Regulatory T Cells in (Pre-)clinical Studies: Their Relevance Is Slowly Recognised.Frontiers in medicine · 2020Pooled it
- Immunological effects of nivolumab immunotherapy in patients with oral cavity squamous cell carcinoma.BMC cancer · 2020Trial
- Non-surgical Synergistic Interventions for the Treatment of Skin Cancer.Current pharmaceutical design · 2026Review
- Immune Checkpoint Inhibitors for Pediatric Cancers: Is It Still a Stalemate?Pharmaceuticals (Basel, Switzerland) · 2024Review
- The progress of microenvironment-targeted therapies in brain metastases.Frontiers in molecular biosciences · 2023Review
- Neoantigens and their clinical applications in human gastrointestinal cancers.World journal of surgical oncology · 2022Review
- Review
- Immunotherapy and radiotherapy in melanoma: a multidisciplinary comprehensive review.Human vaccines & immunotherapeutics · 2022Review
- Immunogenomics in personalized cancer treatments.Journal of human genetics · 2021Review
- Immunotherapy for pancreatic cancer: chasing the light at the end of the tunnel.Cellular oncology (Dordrecht, Netherlands) · 2021Review
- Targeting Genome Stability in Melanoma-A New Approach to an Old Field.International journal of molecular sciences · 2021Review
- Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapy.Nature cancer · 2021Article
- Review
- Nanomaterials for Protein Delivery in Anticancer Applications.Pharmaceutics · 2021Review
- Immune System in Action.Advances in experimental medicine and biology · 2021Article
- Enhanced tumor response to radiotherapy after PD-1 blockade in metastatic gastric cancer.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2020Article
- Inhibitory checkpoints in human natural killer cells: IUPHAR Review 28.British journal of pharmacology · 2020Review
- The emerging role of epigenetic therapeutics in immuno-oncology.Nature reviews. Clinical oncology · 2020Review
- Tumor-Specific Antibody, Cetuximab, Enhances theFrontiers in immunology · 2020Article
- Stereotactic Body Radiotherapy Is Effective in Modifying the Tumor Genome and Tumor Immune Microenvironment in Non-Small Cell Lung Cancer or Lung Metastatic Carcinoma.Frontiers in immunology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 1 institution in 1 country.
Funding
Abstract
We report here on a patient with metastatic melanoma who had extensive brain metastases. After being treated with the sequential combination of whole brain radiation therapy followed by the PD-1-inhibitory antibody, pembrolizumab, the patient had a durable complete response. Retrospective laboratory studies of T cells revealed that, after treatment with anti-PD-1 commenced, effector CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.